The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced a significant management reshuffle in China. Cherry Huang, previously the North Asia Regional Managing Director and CEO of the Korea unit, will succeed Zhen Lei as the president of Xi’an Janssen. In this role, Huang will be responsible for driving business development within the country. Zhen Lei is moving on to pursue external development opportunities.
Cherry Huang’s Appointment and Background
Cherry Huang joined Johnson & Johnson in 1997 as a financial analyst. She progressed through the company to become the financial head of Xi’an Janssen from 2011 to 2015. Huang then served as the Senior Financial Director for Southeast Asia at J&J and Chief Financial Officer for Asia Pacific at Janssen. In May 2021, Huang was appointed as CEO of Janssen’s Korea unit, while also overseeing business operations in Hong Kong and Taiwan.
Implications of the Management Change
This leadership change at Xi’an Janssen is part of a broader strategic move to strengthen the company’s operations in China. Cherry Huang’s extensive experience within J&J and her financial acumen are expected to contribute significantly to the continued growth and success of Janssen’s business in the region.-Fineline Info & Tech
